Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

7934 results

Sort By:

Biopsy Collection for Men Undergoing Brachytherapy for Prostate Cancer

Study ID: NCT04243473
Start Date: 2025-06
End Date: 2033-12
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

50

Intervention / Treatment
Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Source: clinicaltrials.gov

Share:
Add to list

Stool Sample Collection Study

Study ID: NCT06294873
Start Date: 2023-07-20
End Date: 2024-04-30
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

40

Intervention / Treatment

A screening device for the detection of colorectal and other aerodigestive tract cancers

Sponsor

Innovis LLC

Source: clinicaltrials.gov

Share:
Add to list

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

Study ID: NCT06224673
Start Date: 2025-04-15
End Date: 2028-07-31
Study Type

Interventional

Study Phase

Phase2

No. of Participants

36

Intervention / Treatment

Arch788

Computed Tomography (CT)

Biospecimen Collection

Amiloride

Sponsor

Laura Huppert, MD, BA

Source: clinicaltrials.gov

Share:
Add to list

Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers

Study ID: NCT05497531
Start Date: 2022-09-07
End Date: 2025-06
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

15

Intervention / Treatment

ctDNA Blood Collection

Sponsor

University of California, Irvine

Source: clinicaltrials.gov

Share:
Add to list

Use of ACU-D1 in HPV Associated Vulvar and Perianal Lesions in People With HIV

Study ID: NCT06233331
Start Date: 2025-05
End Date: 2026-05
Study Type

Interventional

Study Phase

Phase1

No. of Participants

9

Intervention / Treatment

Dose Level 1 ACU-D1 ointment

Dose Level 2 ACU-D1 ointment

Dose Level 3 ACU-D1 ointment

Vulvar/ Perianal Biopsy

Sponsor

Emory University

Source: clinicaltrials.gov

Share:
Add to list

Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma

Study ID: NCT04656431
Start Date: 2021-06-29
End Date: 2025-03-31
Study Type

Interventional

Study Phase

Phase1

No. of Participants

25

Intervention / Treatment

Hyperpolarized pyruvate (13C)

Magnetic resonance imaging (MRI)

Sponsor

James Rubenstein

Source: clinicaltrials.gov

Share:
Add to list

FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Study ID: NCT06402331
Start Date: 2024-03-05
End Date: 2031-01-23
Study Type

Interventional

Study Phase

Phase3

No. of Participants

100

Intervention / Treatment

FPI-2265

Sponsor

Fusion Pharmaceuticals Inc.

Source: clinicaltrials.gov

Share:
Add to list

Canakinumab for the Prevention of Progression to Cancer in Patients with Clonal Cytopenias of Unknown Significance, IMPACT Study

Study ID: NCT05641831
Start Date: 2023-02-06
End Date: 2028-12-31
Study Type

Interventional

Study Phase

Phase2

No. of Participants

110

Intervention / Treatment

Biospecimen Collection

Bone Marrow Aspiration and Biopsy

Kankinumab

Chest Radiography

Echocardiography

Placebo Administration

Quality-of-Life Assessment

Sponsor

A borate

Source: clinicaltrials.gov

Share:
Add to list

Non-Endoscopic Detection of Barrett's Esophagus Using Methylation Biomarkers on EndoSign® Cell Collection Device Samples

Study ID: NCT06803927
Start Date: 2025-02-05
End Date: 2025-10
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

700

Intervention / Treatment

Barrett's Esophagus Test (LDT)

Sponsor

Cyted Health Inc

Source: clinicaltrials.gov

Share:
Add to list

Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

Study ID: NCT02861573
Start Date: 2016-11-17
End Date: 2027-10-22
Study Type

Interventional

Study Phase

Phase2

No. of Participants

1200

Intervention / Treatment

Pembrolizumab 200 mg

Olaparib 400 mg

Docetaxel 75 mg/m^2

Prednisone 5 mg

Enzalutamide 160 mg

Dexamethasone 8 mg

Olaparib 300 mg

Abiraterone acetate 1000 mg

Lenvew

Pembrolizumab/Vibostolimab coformulation

Carboplatin

Etoposide

Belzutifan 120mg

Sponsor

Merck Sharp & Dohme LLC

Source: clinicaltrials.gov

Share:
Add to list